Regenxbio Inc RGNX

NAS: RGNX | ISIN: US75901B1070   30/04/2025
9,610 USD (+2,13%)
(+2,13%)   30/04/2025

30 april 2025 · REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights · Persbericht

19 maart 2025 · Regenxbio Reports Positive Biomarker Data From Affinity Duchenne® Trial Of Rgx-202 Gene Therapy · Persbericht

13 maart 2025 · REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates · Persbericht

10 maart 2025 · REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference · Persbericht

4 maart 2025 · REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases · Persbericht

3 september 2024 · REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect · Persbericht

29 augustus 2024 · REGENXBIO to Participate in Upcoming Investor Conferences · Persbericht

27 augustus 2024 · REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium · Persbericht

8 augustus 2024 · REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference · Persbericht

1 augustus 2024 · REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights · Persbericht

1 augustus 2024 · Regenxbio Announces New Positive Data From Affinity Duchenne® Trial Of Rgx-202 · Persbericht

25 juli 2024 · REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights · Persbericht

24 juni 2024 · REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients · Persbericht

18 juni 2024 · REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II · Persbericht

12 juni 2024 · REGENXBIO Announces Leadership Transition · Persbericht

5 juni 2024 · REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference · Persbericht

10 mei 2024 · REGENXBIO to Participate in Upcoming Investor Conferences · Persbericht

8 mei 2024 · REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights · Persbericht

1 mei 2024 · REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights · Persbericht

24 april 2024 · REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit · Persbericht

Mijn selecties